Document Classification

Section Type: RESULTS

Text: All-cause mortality 6. 2 % versus 4. 5 % (p = 0. 50) ; reinfarction 0. 4 % versus 3. 5 % (p = 0. 03) ; target vessel revascularization 4. 4 % versus 6. 5 % (p = 0. 40) ; the combined end point of death, nonfatal reinfarction, and target vessel revascularization 10. 6 % versus 10. 9 % (p = 0. 90) ; stroke 0. 5 % versus 0. 5 % (p = 1. 00) after 6 months ; and Thrombolysis In Myocardial Infarction major bleeding complications 4. 0 % versus 2. 0 % (p = 0. 20) after 30 days were observed after eptifibatide and abciximab, respectively.